Industry news

Researchers at Siberian State Medical University use “green chemistry”

GMP News

The researchers of the Siberian State Medical University in Tomsk are developing a biotech method for obtaining antimicrobial peptides to synthesize a drug for radionuclide diagnostics of infectious inflammations.

Investments in the Russian pharmaceutical industry exceeded 120 billion rubles

GMP News

Over the past 6 years, the investments in the Russian pharmaceutical industry exceeded 120 billion rubles, said Sergey Tsyb, the Deputy Minister of Industry and Trade of the Russian Federation, in an interview with Interfax at All-Russian Inter-University GxP Summit.

Report: Biopharma Investments Down in 2016

BioPharm International

Small, emerging companies make up more than 90% of the biopharmaceutical industry and have 4186 drug indication programs—or 70% of the global industry pipeline—under development. A report from the Biotechnology Industry Association (BIO) reviewed at the 2017 BIO convention in San Diego in June 2017 measures the state of investments from venture capital, initial and follow-on public offerings, licensing, and acquisitions that are vital to the ongoing development of small biopharmaceutical companies. Investments were tracked from 2007–2016.

10 July 2017

Neothetics Announces Review of Strategic Alternatives

Neothetics, Inc.  (NASDAQ:NEOT) announced today that its Board of Directors has unanimously approved plans to initiate a process to explore and review a range of strategic alternatives focusing on seeking an acquisition, business combination or partnership that will allow for it to maximize shareholder value from its remaining assets and cash resources. 

Association of Manufacturers of Plant-Based Medicinal Products is established in Russia

GMP News

The Association of Manufacturers and Consumers of Plant-Based Medicinal Products, a new public organization, has been registered by the Russian Ministry of Justice.

FDA Acts to Improve Market Competition

BioPharm International

OOn June 27, 2017, FDA announced it has published a list of off-patent, off-exclusivity branded drugs that do not have generic options. The agency also implemented a new policy to expedite review of generic-drug applications for drugs where competition is limited. These steps were taken as part of the agency’s Drug Competition Action Plan. FDA hopes to increase competition in the pharmaceutical market in order to stimulate lower-cost options for consumersn June 27, 2017, FDA announced it has published a list of off-patent, off-exclusivity branded drugs that do not have generic options. 

U.K. politicians push for cooperation with EMA post-Brexit

Nick Paul Taylor / Fierce Biotech

Senior politicians in the British government have called for the country to work closely with the European Medicines Agency (EMA) after Brexit. The statement suggests the politicians are willing to stand up to colleagues pushing for a clean break from European regulation and want to reassure the industry they will minimize disruption.

Preclinical trials of oncoprotein with iron oxide nanoparticle start in Russia

GMP News

The researchers at the National University of Science and Technology MISiS, Moscow State University and Medical Nanotechnology LLC have begun preclinical trials of a Russian drug for the treatment of cancerous tumors.

New device diagnoses and predicts lung problems

Marchmont Innovation News

At the Far East Center for Respiratory Physiology and Pathology in Blagoveshchensk, in the Amur region some 7,800km east of Moscow, researchers have come up with a new device to diagnose allergy to cold and a range of dangerous respiratory diseases in patients, Ampravda.ru  reported. 

Drugmakers’ Payments to U.K. Health Groups and Doctors Climb 25%

James Paton / Bloomberg

The spending climbed to 455 million pounds ($590 million) last year, according to a report on Friday from the Association of the British Pharmaceutical Industry, which collects the data. Cambridge-based AstraZeneca had the highest expenditure, at 56 million pounds, said Karen Borrer, head of reputation at the lobbying group.